Niacin–Statin Study Didn't Give Desired Results: Stopped Early
The National Institutes of Health stopped a clinical trial studying a blood lipid treatment 18 months early. The study found that adding high dose, extended release niacin to statin treatment for patients with heart disease did not reduce cardiovascular events, such as heart attacks and strokes.
Study Participants
This study was referred to as AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health) and the 3414 participants were selected because they were at risk for cardiovascular events despite having a well controlled LDL cholesterol level. They were at increased risk due to a history of heart disease combined with low HDL cholesterol and high triglycerides. Low HDL levels and high triglycerides are both linked to increased risk of cardiovascular events.
Study participants were divided into two groups.
Lower Cholesterol Effectively – Zetia Versus Niacin
It often feels like pharmaceutical companies often get wrapped up in dollar signs and forget the bottom-line reason for manufacturing the medication – improving your health. A study compared the effectiveness of Niacin versus Zetia.
The study
The study was published in the New England Journal of Medicine this past November 2009. Researchers analyzed the effect of extended-release niacin and ezetimibe (Zetia) on LDL cholesterol and HDL cholesterol levels.
